Countouriotis Athena 4

What Happened
Athena Countouriotis, a director of BioMarin Pharmaceutical Inc. (BMRN), received an award of 7,490 restricted stock units (RSUs) on June 2, 2026. The Form 4 records this as an award/grant (code A) with a reported acquisition price of $0.00 because RSU grants do not have a per‑share purchase price in the filing.

Key Details

• Transaction date: 2026-06-02; Form 4 filed 2026-06-04 (filing appears timely).
• Security / amount: 7,490 restricted stock units; price shown as $0.00 (price not applicable).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: F1 — "Restricted stock units granted on June 2, 2026. Price not applicable."
• Transaction code: A (award/grant).

Context
RSU grants are a form of equity compensation tied to service and/or vesting conditions; they are not purchases or open‑market sales and do not by themselves indicate buying or selling sentiment. Vesting schedule or performance conditions (if any) were not disclosed in the Form 4.